Effects of Atorvastatin on Carotid Atherosclerotic Plaques: A Randomized Trial for Quantitative Tissue Characterization of Carotid Atherosclerotic Plaques with Integrated Backscatter UltrasoundYamada K.a · Yoshimura S.a · Kawasaki M.b · Enomoto Y.a · Asano T.c · Minatoguchi S.b · Iwama T.a
Departments of aNeurosurgery, bCardiology and cRadiology, Gifu University Graduate School of Medicine, Gifu, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Instability of carotid plaques has been reported to be associated with stroke and other cerebrovascular events. The purpose of this study was to examine whether cholesterol-lowering therapy with atorvastatin in nonhypercholesterolemic patients reduces carotid plaque instability as assessed by ultrasound integrated backscatter (IBS) analysis. Methods: Consecutive non- or slightly hypercholesterolemic patients with moderate carotid artery stenosis were randomly assigned to a diet group (n = 20) or a statin group (atorvastatin; n = 20). Carotid plaques were monitored by measuring intima media thickness (IMT) and IBS values at baseline and after 6 months. Results: Three-dimensional IBS imaging showed that relative lipid volume of carotid plaques significantly decreased from 58.4 ± 25.6 to 47.8 ± 23.5% in the statin group (p < 0.01), whereas there was no significant decrease in the diet group. Significant regression of IMT was not observed in either group. The changes of IBS values and relative lipid volume between baseline and 6 months were correlated with the change in low-density lipoprotein cholesterol (r = 0.31, p < 0.05, and r = 0.34, p < 0.05, respectively). Conclusions: Lipid-lowering therapy by atorvastatin decreased relative lipid volume without significant regression of plaque volume during short-term follow-up in patients with moderate carotid artery stenosis. Quantitative assessment of carotid plaques by IBS analysis was clinically useful for monitoring atherosclerotic lesions.
© 2009 S. Karger AG, Basel
Polak JF, Shemanski L, O’Leary DH, Lefkowitz D, Price TR, Savage PJ, Brant WE, Reid C: Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 years or older. The Cardiovascular Health Study. Radiology 1998;208:649–654.
- Gronholdt ML, Nordestgaard BG, Schroeder TV, Vorstrup S, Sillesen H: Ultrasonic echolucent carotid plaques predict future strokes. Circulation 2001;104:68–73.
- Amarenco P, Bogousslavsky J, Callahan A 3rd, et al, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–559.
- Waters DD, Schwartz GG, Olsson AG, et al, for the MIRACLE study investigator: Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction. A myocardial ischemia reduction with aggressive cholesterol lowing (MIRACLE) substudy. Circulation 2002;196:1690–1695.
- Libby P, Aikawa M: Stabilization of atherosclerotic plaques new mechanisms and clinical targets. Nat Med 2002;8:1257–1262.
- Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma a potential mechanism of lesion stabilization. Circulation 1998;97:2433–2444.
- Takiuchi S, Rakugi H, Honda K, Masuyama T, Hirata N, Ito H, Sugimoto K, Yanagitani Y, Moriguchi K, Okamura A, Higaki J, Ogihara T: Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. Circulation 2000;102:766–770.
- Kawasaki M, Takatsu H, Noda T, Ito Y, Kunishima A, Arai M, Nishigaki K, Takemura G, Morita N, Minatoguchi S, Fujiwara H: Non-invasive tissue characterization of human atherosclerotic lesions in carotid and femoral arteries by ultrasound integrated backscatter. Comparison between histology and integrated backscatter images before and after death. J Am Coll Cardiol 2001;38:486–492.
- Kawasaki M, Ito Y, Yokoyama H, Arai M, Takemura G, Hara A, Ichiki Y, Takatsu H, Minatoguchi S, Fujiwara H: Assessment of arterial medial characteristics in human carotid arteries using integrated backscatter ultrasound and its histological implications. Atherosclerosis 2005;180:145–154.
- Nagano K, Yamagami H, Tsukamoto Y, Nagatsuka K, Yasaka M, Nagata I, Hori M, Kitagawa K, Naritomi H: Quantitative evaluation of carotid plaque echogenicity by integrated backscatter analysis: correlation with symptomatic history and histologic findings. Cerebrovasc Dis 2008;26:578–583.
- Furukado S, Sakaguchi M, Yamagami H, Yagita Y, Hoshi T, Abe Y, Hougaku H, Hori M, Sakoda S, Kitagawa K: Cyclo-oxygenase-2 –765G > C promoter variants are associated with lower carotid plaque echogenicity in Japanese. Cerebrovasc Dis 2009;27:91–98.
- Yuan C, Mitsumori LM, Ferguson MS, Polissar NL, Echelard D, Ortiz G, Small R, Davis JW, Kerwin WS, Hatsukami TS: In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 2001;104:2051–2056.
- Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT: Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758–1764.
Salonen JT, Salonen R: Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993;87(suppl II):II-56–II-65.
- Mannami T, Konishi M, Baba S, Nishi N, Terao A: Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city. Stroke 1997;28:518–525.
- Ainsworth CD, Blake CC, Tamayo A, Baletsky V, Fenster A, Spence JD: 3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies. Stroke 2005;35:1904–1909.
- Amarenco P, Labreuche J, Lavallee P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis. System review and up-to-date meta-analysis. Stroke 2004;35:2902–2909.
Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.Lancet 2001;357:577–581.
- Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJP, Grundy SM: Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol 2006;48:1793–1799.
- Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757–767.
- Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262–1275.
- Wasserman BA, Wityk RJ, Trout HH 3rd, Virmani R: Low-grade carotid stenosis. Looking beyond the lumen with MRI. Stroke 2005;36:2504–2513.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.